Cytokinetics, Incorporated (CYTK) vs Praxis Precision Medicines, Inc. (PRAX)
A side-by-side comparison of Cytokinetics, Incorporated and Praxis Precision Medicines, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CYTK
Cytokinetics, Incorporated
$61.47HealthcareDelayed quote: Oct 6, 2026, 12:30 PM EDT
PRAX
Praxis Precision Medicines, Inc.
$277.19HealthcareDelayed quote: Oct 6, 2026, 12:30 PM EDT
Total return — CYTK vs PRAX
growth of $100 · dividends reinvested · last 6yCYTK +280.7% (+25.0%/yr)PRAX -32.0% (-6.2%/yr)CYTK compounded faster over this window
Log scale — wide-divergence pair
CYTK PRAX
CYTK vs PRAX: by the numbers
- •PRAX is the larger company ($7.73B vs $7.65B market cap).
- •Both run net losses; PRAX's is the smaller (0.00% vs -1259.87% net margin).
Metrics side by side
Valuation
| Metric | CYTK | PRAX |
|---|---|---|
| P/S ratio | 107.78 | N/A |
| P/B ratio | N/A | 5.76 |
Profitability
| Metric | CYTK | PRAX |
|---|---|---|
| Gross margin | 84.97% | 0.00% |
| Operating margin | -695.44% | 0.00% |
| Net margin | -1259.87% | 0.00% |
| ROE | N/A | -25.29% |
| ROIC | -39.80% | -28.18% |
Growth (annualized)
| Metric | CYTK | PRAX |
|---|---|---|
| Revenue CAGR (5Y) | 4.19% | N/A |
| Total return CAGR (5Y) | 11.24% | -0.21% |
Frequently asked
- How have CYTK and PRAX total returns compared?
- Over the past 5 years, CYTK delivered 11.24% and PRAX delivered -0.21% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Cytokinetics ROEPraxis Precision Medicines ROECytokinetics operating marginPraxis Precision Medicines operating marginCytokinetics revenue growthPraxis Precision Medicines revenue growthCytokinetics free cash flowPraxis Precision Medicines free cash flow
Cytokinetics & Praxis Precision Medicines appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.